It’s traditional that the December CPD module reviews some of the key changes in therapeutics and practice that took place during the previous year and summarises those medicines safety issues that have implications for pharmacy customers. Changes to clinical guidelines that are of relevance to pharmacy practice are also covered, as well as new medicine launches. 

Medicines causing birth defects or issues in pregnancy

Valproate (Epilim, Depakote) must no longer be used in women or girls of childbearing age unless a pregnancy prevention programme is in place and there is no alternative medicine available. Medicines containing valproate taken during pregnancy can cause malformations in 11 per cent of babies and developmental disorders in 30-40 per cent of children after birth. 

Women and girls must be fully informed of the risks and the need to avoid exposure to valproate medicines in pregnancy. GPs should have contacted all patients and provided a patient guide in addition to ensuring patients have seen a specialist in the last year and are on highly effective contraception.

NICE has updated guidelines relevant to valproate medicines to reflect the regulatory changes.